Estimation of the poliovirus type 2 immunity gap in South Africa.

IPV Immunity Poliovirus South Africa Vaccination Zero-dose children

Journal

Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899

Informations de publication

Date de publication:
04 Jul 2024
Historique:
received: 22 03 2024
revised: 10 06 2024
accepted: 10 06 2024
medline: 6 7 2024
pubmed: 6 7 2024
entrez: 5 7 2024
Statut: aheadofprint

Résumé

In the context of polio eradication efforts, accurate assessment of vaccination programme effectiveness is essential to public health planning and decision making. Such assessments are often based on zero-dose children, estimated using the number of children who did not receive the first dose of the Diphtheria-Tetanus-Pertussis containing vaccine as a proxy. Our study introduces a novel approach to directly estimate the number of children susceptible to poliovirus type 2 (PV2) and uses this approach to provide district-level estimates for South Africa of susceptible children born between 2017 and 2022. We used district-level data on annual doses of inactivated poliovirus vaccine (IPV) administered, live births, and population sizes, from 2017 through 2022. We imputed missing vaccination data, implemented flexible assumptions regarding dose distribution in the eligible population, and used estimated efficacy values for one, two, three, and four doses of IPV, to compute the number of susceptible and immune children by birth year. We validated our approach by comparing an intermediary output with zero-dose children (ZDC) estimated using data reported by WHO/UNICEF Estimates of National Immunization Coverage (WUENIC). Our results indicate high heterogeneity in susceptibility to PV2 across South Africa's 52 districts as of the end of 2022. In children under 5 years, PV2 susceptibility ranged from approximately 30 % in districts including Xhariep (31.9 %), Ekurhuleni (30.1 %), and Central Karoo (29.8 %), to less than 4 % in Sarah Baartman (1.9 %), Buffalo City (2.1 %), and eThekwini (3.2 %). Our susceptibility estimates were consistently higher than ZDC over the timeframe. We estimated that ZDC decreased nationally from 155,168 (152,737-158,523) in 2017 to 108,593 in 2021, and increased to 127,102 in 2022, a trend consistent with ZDC derived from data reported by WUENIC. While our approach provides a more comprehensive profile of PV2 susceptibility, our susceptibility and ZDC estimates generally agree in the ranking of districts according to risk.

Identifiants

pubmed: 38969540
pii: S0264-410X(24)00703-5
doi: 10.1016/j.vaccine.2024.06.029
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Lauren Brown (L)

South African Centre for Epidemiological Modelling and Analysis (SACEMA), Stellenbosch University, Stellenbosch, South Africa.

Jeremy Bingham (J)

South African Centre for Epidemiological Modelling and Analysis (SACEMA), Stellenbosch University, Stellenbosch, South Africa. Electronic address: jeremyb@sun.ac.za.

Juliet Pulliam (J)

South African Centre for Epidemiological Modelling and Analysis (SACEMA), Stellenbosch University, Stellenbosch, South Africa.

Zinhle Mthombothi (Z)

South African Centre for Epidemiological Modelling and Analysis (SACEMA), Stellenbosch University, Stellenbosch, South Africa.

Tumelo Sereo (T)

South African Centre for Epidemiological Modelling and Analysis (SACEMA), Stellenbosch University, Stellenbosch, South Africa.

Mercy Kamupira (M)

UNICEF, South Africa.

Sonia Botha (S)

Western Cape Department of Health, Expanded Programme on Immunisation, City of Cape Town, South Africa.

Koko Molema (K)

National Department of Health, Expanded Programme on Immunisation, Pretoria, South Africa.

Elizabeth Maseti (E)

National Department of Health, Expanded Programme on Immunisation, Pretoria, South Africa.

Marione Schönfeldt (M)

National Department of Health, Expanded Programme on Immunisation, Pretoria, South Africa.

Nicoletta Mabhena (N)

Right to Care, Centurion, Pretoria, South Africa.

Nishi Prabdial-Sing (N)

National Institute for Communicable Diseases, Division of the National Health Laboratory Service, Johannesburg, South Africa.

Anne von Gottberg (A)

National Institute for Communicable Diseases, Division of the National Health Laboratory Service, Johannesburg, South Africa.

Kerrigan McCarthy (K)

National Institute for Communicable Diseases, Division of the National Health Laboratory Service, Johannesburg, South Africa.

Cari van Schalkwyk (C)

South African Centre for Epidemiological Modelling and Analysis (SACEMA), Stellenbosch University, Stellenbosch, South Africa.

Classifications MeSH